A Phase 2 interventional study of vorinostat and vorinostat in Myelodysplastic Syndromes, Blood Disease and Bone Marrow Disease, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-03.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing vorinostat in Myelodysplastic Syndromes — none open to participants now, 3 under way, none of them phase 3. Vorinostat · Myelodysplastic Syndromes.
Among the 11 studies testing vorinostat in Myelodysplastic Syndromes, this one is the 7th largest by enrollment, is one of 2 that started in 2007, is one of 5 in phase 2, and was the 3rd registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →None of the 11 studies testing vorinostat in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8
First in 2006; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 43 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 7 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
15 studies in Myelodysplastic Syndromes by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 15 finished, 9 (60%) have results posted.
Among the 15 studies in Myelodysplastic Syndromes by Merck & Co., Inc, this one is the 14th largest by enrollment, is one of 3 that started in 2007, is one of 6 in phase 2, and was the 8th registered.
Merck & Co., Inc’s Myelodysplastic Syndromes studies by the year they started, since 2001.
2 of the studies testing vorinostat in Myelodysplastic Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00392353National Cancer Institute (NCI)Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | 2026-12-31 |
| NCT03843528Johns Hopkins All Children's HospitalVorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | 2027-07-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing vorinostat in Myelodysplastic Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 15 in Myelodysplastic Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the efficacy, safety and tolerability of vorinostat in patients with lower risk Myelodysplastic Syndrome (MDS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient is a male or female, at least 18 years of age with low or intermediate-1 risk Myelodysplastic Syndrome (MDS) defined by the International Prognostic Scoring System
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
vorinostat 400 mg
Drug: vorinostat
vorinostat 200 mg
Drug: vorinostat
vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
Also known as: suberoylanilide hydroxamic acid (SAHA), ZOLINZA®
vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
Also known as: suberoylanilide hydroxamic acid (SAHA), ZOLINZA®
Number of Responders and Number of Non-responders Defined by International Working Group Response Criteria
Number of responders is defined as the number of patients in the analysis population who have complete response (CR), partial response (PR), or hematologic improvement (HI) per International Working Group Response Criteria during the course of the study. Confirmation of CR or PR will require a second assessment performed 4 weeks or more after the initial assessment. Confirmation of HI will require a second assessment performed 8 weeks or more after the initial assessment. Number of non-responders is defined as the number of patients who did not achieve CR, PR or HI in the study.
Time frame: 2 Years
Safety and Tolerability as Assessed by the Number of Participants With Adverse Events.
Time frame: Every 21 days while on therapy and at 30 days after the last dose of study therapy
Date of first patient in was 26-Jun-2007. The date of last patient last visit for the study was 16-Jul-2009.
| Milestone | Vorinostat Once Daily Dose Schedule | Vorinostat Thrice Daily Dose Schedule |
|---|---|---|
| Started | 10 | 12 |
| Completed | 0 | 0 |
| Not completed | 10 | 12 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lack of efficacy | 4 | 6 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Progressive disease | 0 | 1 |
Number of responders is defined as the number of patients in the analysis population who have complete response (CR), partial response (PR), or hematologic improvement (HI) per International Working Group Response Criteria during the course of the study. Confirmation of CR or PR will require a second assessment performed 4 weeks or more after the initial assessment. Confirmation of HI will require a second assessment performed 8 weeks or more after the initial assessment. Number of non-responders is defined as the number of patients who did not achieve CR, PR or HI in the study.
| Participants | Vorinostat Once Daily Dose Schedule | Vorinostat Thrice Daily Dose Schedule |
|---|---|---|
| Responder | 0 | 0 |
| Non-responder | 9 | 12 |
| Participants | Vorinostat Once Daily Dose Schedule | Vorinostat Thrice Daily Dose Schedule |
|---|---|---|
| With one or more adverse events | 9 | 12 |
| With no adverse events | 0 | 0 |
| With drug-related adverse events | 4 | 11 |
| With serious adverse events | 2 | 5 |
| With serious drug-related adverse events | 0 | 2 |
Collected over Serious and non-serious adverse experiences occurring from the time of consent up through 30 days after the last dose of study drug were reported.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vorinostat Once Daily Dose Schedule | — | 2/9 (22.2%) | 9/9 (100%) |
| Vorinostat Thrice Daily Dose Schedule | — | 5/12 (41.7%) | 12/12 (100%) |
| Event | Vorinostat Once Daily Dose Schedule | Vorinostat Thrice Daily Dose Schedule |
|---|---|---|
| Disease progressionGeneral disorders | 1/9 | 0/12 |
| Lung infectionInfections and infestations | 1/9 | 0/12 |
| PneumoniaInfections and infestations | 1/9 | 0/12 |
| Urinary tract infectionInfections and infestations | 1/9 | 0/12 |
| Confusional statePsychiatric disorders | 1/9 | 0/12 |
| Urinary retentionRenal and urinary disorders | 1/9 | 0/12 |
| AnaemiaBlood and lymphatic system disorders | 0/9 | 1/12 |
| NeutropeniaBlood and lymphatic system disorders | 0/9 | 1/12 |
| Splenic haemorrhageBlood and lymphatic system disorders | 0/9 | 1/12 |
| Pericardial effusionCardiac disorders | 0/9 | 1/12 |
| Event | Vorinostat Once Daily Dose Schedule | Vorinostat Thrice Daily Dose Schedule |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/9 | 11/12 |
| NauseaGastrointestinal disorders | 5/9 | 9/12 |
| AnaemiaBlood and lymphatic system disorders | 1/9 | 7/12 |
| FatigueGeneral disorders | 4/9 | 7/12 |
| VomitingGastrointestinal disorders | 4/9 | 5/12 |
| AnorexiaMetabolism and nutrition disorders | 1/9 | 5/12 |
| NeutropeniaBlood and lymphatic system disorders | 2/9 | 4/12 |
| HypokalaemiaMetabolism and nutrition disorders | 0/9 | 4/12 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/9 | 0/12 |
| DizzinessNervous system disorders | 2/9 | 3/12 |
| Age, Continuous(years) | Vorinostat Once Daily Dose Schedule | Vorinostat Thrice Daily Dose Schedule | Total |
|---|---|---|---|
| Mean | 69.0 ± 18.5 | 64.0 ± 10.5 | 66.0 ± 14.1 |
| Sex: Female, Male(Participants) | Vorinostat Once Daily Dose Schedule | Vorinostat Thrice Daily Dose Schedule | Total |
|---|---|---|---|
| Female | 1 | 5 | 6 |
| Male | 8 | 7 | 15 |
| Race/Ethnicity, Customized(participants) | Vorinostat Once Daily Dose Schedule | Vorinostat Thrice Daily Dose Schedule | Total |
|---|---|---|---|
| White | 9 | 10 | 19 |
| Black | 0 | 1 | 1 |
| Asian | 0 | 1 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Scale Status(participants) | Vorinostat Once Daily Dose Schedule | Vorinostat Thrice Daily Dose Schedule | Total |
|---|---|---|---|
| 0 = Normal Activity | 4 | 10 | 14 |
| 1 = Symptoms, but ambulatory | 4 | 1 | 5 |
| 2 = In bed < 50% of the time | 1 | 1 | 2 |
| International Prognostic Scoring System Risk (IPSS)(Participants) | Vorinostat Once Daily Dose Schedule | Vorinostat Thrice Daily Dose Schedule | Total |
|---|---|---|---|
| Low | 3 | 4 | 7 |
| Intermediate-1 | 6 | 8 | 14 |
| Prior Myelodysplastic Syndromes Therapy(Participants) | Vorinostat Once Daily Dose Schedule | Vorinostat Thrice Daily Dose Schedule | Total |
|---|---|---|---|
| Yes | 6 | 3 | 9 |
| No | 3 | 9 | 12 |
No study locations are listed for this record.
The record gives a start of Jun 2007, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat